Loading…
← CockpitCompetitor Analysis › 6901.TW Diamond BioFund Inc.Open in the cockpit ↗

Diamond BioFund Inc.6901.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Financials›Investment Managers
Momentum neutral 50
Mkt cap
$338M
US dollars, full cap
Free float
36%
of shares outstanding
$/day
$663,379
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.7%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · TWDNT$13.80
1D-0.4%
1W-1.4%
1M-21.6%
3M-16.4%
6M-0.7%
YTD-16.4%
1Y-23.1%
ATR %4.7%
52w lowhigh38.4% off high

What Diamond BioFund does

No business profile yet.

Diamond BioFund at a glance

Size Diamond BioFund (6901.TW) is a Taiwan Financials company (Investment Managers) with a market value of $338M, the 584th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$13.80 on 18 Nov 2026.

Performance Over six months the shares fell 0.7%, against -12.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 153.0% over the last twelve months (peer median +15.5%); the operating margin is 3,484,110.1% (peer median 31.1%).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 20266901.TW 101Peer median 89
Six months, rebased to 100: Diamond BioFund against the median of its 20 peers (local-currency closes).

Diamond BioFund financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$69,000-NT$596,000NT$1.12MNT$2.24MNT$418,000
Revenue growth—-153%-50%+437%—
EBITDANT$2.43B-NT$1.25B-NT$2.38B-NT$2.59BNT$890M
Net incomeNT$2.45B-NT$1.17B-NT$2.52B-NT$2.58BNT$798M
Free cash flow-NT$68.5M-NT$166M-NT$130M-NT$215M-NT$246M
Capital expenditureNT$603,000NT$740,000NT$14.8MNT$19.5MNT$2.05M
Total debtNT$75.5MNT$93.9MNT$118MNT$129MNT$3.67M

Quarterly statements and history in the cockpit →

Diamond BioFund competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%-10%0%+10%AEF6000539552CMSINFOEQV1V0806EQTMYFWABCABPMPBEE0133DBAN6686FLAT-B8739CRAMCQAL5842RPL6901.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Diamond BioFund is the large dot.

Diamond BioFund competitors and peer comparison

How Diamond BioFund compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Diamond BioFund against its 20 peers (data as of 18 Nov 2026)
Measure6901.TWPeer medianRank in peer set
1-month return-21.6%-1.8%lowest of 21
6-month return-0.7%-12.1%7th highest of 21
Distance from 52-week high-38.4%-30.9%8th lowest of 21
Revenue growth (TTM)-153.0%+15.5%lowest of 21
Operating margin3,484,110.1%31.1%highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Diamond BioFund 6901.TWTaiwan$338M-1%-153%3,484,110%n/an/an/a
Australian Ethical Investment AEF.AXAustralia$334M+11%+9%30%n/an/an/a
Kunwu Jiuding Investment 600053.SSChina$347M-44%-1%-133%n/an/an/a
Quants Research Institute 9552.TJapan$350M+81%+35%29%n/an/an/a
CMS Info Systems CMSINFO.NSIndia$352M-33%+4%15%n/an/an/a
eQ Oyj EQV1V.HEFinland$357M-16%0%45%n/an/an/a
Value Partners 0806.HKHong Kong$319M-32%+164%39%n/an/an/a
EQT EQT.AXAustralia$372M+36%-7%30%n/an/an/a
First Western Financial MYFWUnited States$302M+9%+6%24%n/an/an/a
ABC arbitrage ABCA.PAFrance$380M+14%+14%44%n/an/an/a
B.P. Marsh & Partners BPM.LUnited Kingdom$297M-5%+31%121%n/an/an/a
PensionBee PBEE.LUnited Kingdom$402M-10%+37%-13%n/an/an/a
China Merchants China Direct Investments 0133.HKHong Kong$409M-12%+81%-99%n/an/an/a
Deutsche Beteiligungs DBAN.DEGermany$410M-22%+46%-20%n/an/an/a
Noah 6686.HKHong Kong$440M-45%+5%32%n/an/an/a
Flat Capital FLAT-B.STSweden$469M-20%+2,082%-707%n/an/an/a
Sparx 8739.TJapan$473M+14%+30%52%n/an/an/a
Canara Robeco Asset Management CRAMC.NSIndia$489M-4%+17%62%n/an/an/a
Qualitas QAL.AXAustralia$513M-12%+12%46%n/an/an/a
Integral 5842.TJapan$518M-27%-2%103%n/an/an/a
Regal Partners RPL.AXAustralia$520M-25%+97%56%n/an/an/a

Questions

Which companies are Diamond BioFund's closest peers?
The cockpit's peer set: Australian Ethical Investment (AEF.AX), Kunwu Jiuding Investment (600053.SS), Quants Research Institute (9552.T), CMS Info Systems (CMSINFO.NS), eQ Oyj (EQV1V.HE), Value Partners (0806.HK), EQT (EQT.AX), First Western Financial (MYFW).
How has Diamond BioFund stock performed?
Over six months to 18 Nov 2026 the shares returned -0.7% against -12.1% for the median peer; over one year -23.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.